Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: J Surg Res. 2015 Mar 18;196(2):404–415. doi: 10.1016/j.jss.2015.03.026

Figure 3.

Figure 3

The effect of Paclitaxel on hASC viability. A. Cytotoxicity of Paclitaxel in hASCs and fibroblasts after 1 day of treatment. MTT Assay revealed hASCs were selectively more cytotoxic to Paclitaxel than fibroblasts. Both 0.01μM and 1μM doses of Paclitaxel were significantly more cytotoxic to hASCs than fibroblasts (p=0.02 and p=0.008). B. Cytotoxicity of Paclitaxel in hASCs and fibroblasts after 3 days of treatment. MTT Assay revealed a similar trend to the 1-day treatment; hASCs were selectively more cytotoxic to Paclitaxel than fibroblasts at the following doses: (0.1μM: p=0.025, 1μM: p=0.011, 3μM: p=0.01, and 30μM: p=0.045).

HHS Vulnerability Disclosure